78 related articles for article (PubMed ID: 28509595)
1. Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
Nagai H; Shimomura T; Takeuchi M; Hanada S; Komeno T; Sunami K; Hidaka M; Yano T; Kitano K; Yoshida I; Inoue N; Saito A; Horibe K; Motitani S; Ichihara S; Watanabe T; Sawamura M
Leuk Lymphoma; 2017 Dec; 58(12):2845-2851. PubMed ID: 28509595
[TBL] [Abstract][Full Text] [Related]
2. Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
Hsu YT; Wu SJ; Kao HW; Hsiao SY; Liao CK; Chen TY; Wang MC
Cancer; 2024 Jun; 130(11):1972-1981. PubMed ID: 38306242
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as a therapeutic option for patients with advanced melanoma.
Winkler JK; Schiller M; Bender C; Enk AH; Hassel JC
Cancer Immunol Immunother; 2018 Jun; 67(6):917-924. PubMed ID: 29516155
[TBL] [Abstract][Full Text] [Related]
4. The aggravating fury rituximab obliterated.
Mahadevia H; Al-Obaidi A; Cossor F
Haematologica; 2024 Jun; 109(6):2016-2018. PubMed ID: 38268447
[No Abstract] [Full Text] [Related]
5. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
6. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
Fanale MA; Cheah CY; Rich A; Medeiros LJ; Lai CM; Oki Y; Romaguera JE; Fayad LE; Hagemeister FB; Samaniego F; Rodriguez MA; Neelapu SS; Lee HJ; Nastoupil L; Fowler NH; Turturro F; Westin JR; Wang ML; McLaughlin P; Pinnix CC; Milgrom SA; Dabaja B; Horowitz SB; Younes A
Blood; 2017 Jul; 130(4):472-477. PubMed ID: 28522441
[TBL] [Abstract][Full Text] [Related]
7. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
Katsuya H; Shimokawa M; Ishitsuka K; Kawai K; Amano M; Utsunomiya A; Hino R; Hanada S; Jo T; Tsukasaki K; Moriuchi Y; Sueoka E; Yoshida S; Suzushima H; Miyahara M; Yamashita K; Eto T; Suzumiya J; Tamura K
Blood; 2017 Jul; 130(1):39-47. PubMed ID: 28515095
[TBL] [Abstract][Full Text] [Related]
8. Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi.
Luminari S; Viel E; Ferreri AJM; Zaja F; Chimienti E; Musuraca G; Tucci A; Balzarotti M; Tani M; Salvi F; Pesce EA; Ferrari A; Liberati AM; Spadea A; Marino D; Bruno-Ventre M; Volpetti S; Bottelli C; Ravaioli E; Merli F; Spina M
Hematol Oncol; 2018 Feb; 36(1):68-75. PubMed ID: 28524259
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
[TBL] [Abstract][Full Text] [Related]
10. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Tsuyama N; Sakata S; Baba S; Mishima Y; Nishimura N; Ueda K; Yokoyama M; Terui Y; Hatake K; Kitagawa M; Ishizuka N; Tomita N; Takeuchi K
Blood; 2017 Jul; 130(4):489-500. PubMed ID: 28522442
[TBL] [Abstract][Full Text] [Related]
11. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Lim SM; Kim HR; Lee JS; Lee KH; Lee YG; Min YJ; Cho EK; Lee SS; Kim BS; Choi MY; Shim HS; Chung JH; La Choi Y; Lee MJ; Kim M; Kim JH; Ali SM; Ahn MJ; Cho BC
J Clin Oncol; 2017 Aug; 35(23):2613-2618. PubMed ID: 28520527
[TBL] [Abstract][Full Text] [Related]
12. Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?
Witzig TE
J Clin Oncol; 2017 Aug; 35(22):2459-2460. PubMed ID: 28514184
[No Abstract] [Full Text] [Related]
13. Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.
Bech RS; Nielsen KL; Larsen TS; Bentzen HH; Lynggaard LS; Do TH; Braendstrup P; Brady J; Mikhaeel NG; Dybkaer K; Johnsen HE; Jensen P; Bøgsted M; El-Galaly TC
Br J Haematol; 2018 Jul; 182(2):297-301. PubMed ID: 28542714
[No Abstract] [Full Text] [Related]
14. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
Bento L; Boumendil A; Finel H; Le Gouill S; Amorim S; Monjanel H; Bouabdallah R; Bay JO; Nicolas-Virelizier E; McQuaker G; Rossi G; Johnson R; Huynh A; Ceballos P; Rambaldi A; Bachy E; Malladi R; Orchard K; Pohlreich D; Tilly H; Bonifazi F; Poiré X; Guilhot F; Haenel A; Crawley C; Metzner B; Gribben J; Russell NH; Damaj G; Thomson K; Dreger P; Montoto S
Bone Marrow Transplant; 2017 Aug; 52(8):1120-1125. PubMed ID: 28530668
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
16. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
Koinis F; Agelaki S; Karavassilis V; Kentepozidis N; Samantas E; Peroukidis S; Katsaounis P; Hartabilas E; Varthalitis II; Messaritakis I; Fountzilas G; Georgoulias V; Kotsakis A
Br J Cancer; 2017 Jun; 117(1):8-14. PubMed ID: 28510571
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM; Kim YH; Horwitz SM; Dummer R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Trotman J; Taylor K; Dalle S; Weichenthal M; Walewski J; Fisher D; Dréno B; Stadler R; Feldman T; Kuzel TM; Wang Y; Palanca-Wessels MC; Zagadailov E; Trepicchio WL; Zhang W; Lin HM; Liu Y; Huebner D; Little M; Whittaker S; Duvic M;
Lancet; 2017 Aug; 390(10094):555-566. PubMed ID: 28600132
[TBL] [Abstract][Full Text] [Related]
18. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
García-Noblejas A; Cannata-Ortiz J; Conde E; González Barca E; Gutiérrez N; Rojas R; Vidal MJ; Ramírez MJ; Jiménez-Ubieto A; García-Ruiz JC; Sancho JM; López A; Ríos Rull P; Novelli S; Albo C; Debén G; López-Guillermo A; Nicolás C; González de Villambrosia S; Mercadal S; Martín García-Sancho A; Arranz R
Ann Hematol; 2017 Aug; 96(8):1323-1330. PubMed ID: 28536895
[TBL] [Abstract][Full Text] [Related]
19. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
[TBL] [Abstract][Full Text] [Related]
20. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
Christopoulos P; Engel-Riedel W; Grohé C; Kropf-Sanchen C; von Pawel J; Gütz S; Kollmeier J; Eberhardt W; Ukena D; Baum V; Nimmrich I; Sieder C; Schnabel PA; Serke M; Thomas M
Ann Oncol; 2017 Aug; 28(8):1898-1902. PubMed ID: 28535181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
